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NON-VALVULAR ATRIAL FIBRILLATION AND STROKE: 
IMPLICATIONS FOR MANAGEMENT 
M. K. Tilney 
ABSTRACT 
Nonvalvular Atrial Fibrillation is more prevalent with increasing age. It is 
associated with a six-fold excess risk of stroke; and a cumulative lifetime stroke risk 
of 35%. 15% of ischaemic strokes are directly attributable to it. Five trials have 
established the safety of warfarin in reducing the risk by 70% in well selected 
patients, with stringent monitoring. Thromboembolism, cardiac failure, 
hypertension and echocardiographic abnormalities identify higher risk patients. The 
management of NV AF is changing from rate control, to cardioversion and 
anticoagulation (or use of antithrombotics) to reduce the embolic risk. 
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Introduction 
Atrial fibrillation (AF) has been described as "the 
grandfather" of cardiac arrhythrnias, being 
known as "The Arrhythmia Perpetua" in the 19th 
century whence its management has remained 
almost unchanged, depending mainly upon 
digoxin and other drugs, and more recently on 
D.e. cardioversion. 
Incidence and Prevalence of AF 
The Framingham study found an overall 
incidence of AF of 1.7% 1, other studies have 
revealed higher rates depending upon the source 
of the population studied. An average of 2.5% of 
those over 60 years are said to be in atrial 
fibrillation with the incidence increasing with 
agc. One 5-year study found a prevalence of 50 
rising to 90 per thousand in the elderly 2, while 
the Framingham study revealed a prevalence of 
up to 8.8% at 80 - 89 years. Campbe\l et al 
carried out an electrocardiographic survey of 
over 65 year olds registered in clinics, and found 
that 2% of 64 year to 70 year olds were in AF, 
rising to 5% In the over 75 year olds:1. There 
was no significant difference between the sexes 
in all the studies. 
Causes of AF 
Atrial fibrillation (AF) is found six times more 
frequently in rheumatic heart disease and cardiac 
TABLE I - Precursors of Atrial Fibrillation 
A. Cardiac: 
Rheumatic heart disease 

Cardiac failure 

Hypertensive heart disease with left 

ventricular hypertrophy 

"Lone" atrial fibrillation 

Cardiomyopathies 

Wolf-Parkinson White Syndrome 

Pre-excitation 

Sinus node disease 

"Holiday" heart (Alcohol induced) 

Atrial septal defect 

B. Non-Cardiac: 
Hyperthyroidism 

Chronic lung disease 

Post-operative (pulmonary surgery) 

Hodgkin's disease. 
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failure '. It is associated with hypertension only 
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in the presence of left ventricular hypertrophy, 
when there is an excess risk of developing AF of 
1.6-1.8. "Lone" atrial fibrillation describes a 
generally benign condition, in those under 60 
years, with no clinical, radiological or 
echocardiographical evidence of heart disease. 
Hyperthyroidism and alcohol are well known 
causes of AF, the latter causing the so-called 
"Holiday heart". 
In the Framingham study, diabetes mellitus was 
also found to be associated with a 2 to 3 fold risk 
of developing AF 1. 
The basic pathology is thought to be myocardial 
damage predisposing to atrial dilatatIOn; 
interestingly ischaemic heart disease was not 
significantly related to the development of AF I. 
Prognosis of AF 
This is described as 'grave' in the Framingham 
Study 1; the mortality is doubled and within this 
figure, the cardiovascular mortality is doubled 1. 
As regards morbidity, AF was associated with a 
six-fold increased risk of strokes, which were 
large with disabling residual deficits. 
Stroke appeared to predispose to AF; it is thought 
that in these cases paroxysmal AF was occurring, 
throwing off emboli, then reverting to sinus 
rhythm. The incidence of embolism is higher 
than is generally thought (see Table 11). Similar 
figures have been found by Hurst et al in 
patients with mitral valve disease and coronary 
artery disease (1964), and by Aberg (1969) in a 
study of 642 cases with AF. An 
epidemiological study of 'Lone' AF based on life 
insurance records also showed an increased 
mortality5, which seems contrary to other 
studies 6. Overall this information shows that AF 
is not as benign as was previously thought. 
Further evidence to support this will now be 
discussed. 
Atrial Fibrillation and Stroke 
Atrial fibrillation has been found in 15% of all 
ischaemic strokes, and 2-8% of patients with 
transient ischaemic attacks. There is an annual 
incidence of 2.5% of ischaemic stroke in non­
valvular AF ( NVAF) with a cumulative lifetime 
risk of 35% 4. Lone AF has been found to have a 
low stroke risk of 0.4-1 % annually 6. 
Secondary emboli, that is embolisation after a 
stroke are most frequent in the first year, 
especially in the first two weeks. The stroke 
recurrence rate is 15% in the first year, and 5% 
thereafter. The mortality after embolic stroke is 
5%, with NV AF being the most common 
embolic source. It is note-worthy that 26% of 
NV AF patients with no history of 
cerebrovascular ischaemia are found to have 
silent infarcts on CT brain scans 7; perhaps this 
fact explains why a lower incidence of infarcts 
was found clinically in younger subgroups of 
patients with NV AF. This information has been 
available for some years; however whether to 
treat with antithrombotics was controversial until 
recently. 
AF: An Independent Risk Factor for Stroke 
AF can coexist with atheroma, indeed there is an 
Increased frequency of both In the elderly, 
however a number of factors point to an 
independent risk status. Following the- onset of 
sustained AF, the embolic risk facror IS 
particularly high - thyrotOXIC AF is associated 
with a 30% embolic rate 8. The Framingham 
study showed a low aSSOCIatIOn between 
ischaemic heart disease and AF, but AF patients 
have a four fold increase in stroke. Autopsy 
studies have shown that ischaemic stroke in AF 
due to cardiogenic embolus varies from 50­
71 % 9. 'Furthermore, angiography has shown 
significant cervical carotid artery stenosis in 
fewer than 10% of stroke patients with AF, this 
is much lower than expected in the average 
stroke population 10. 
Lacunar infarcts are thought to be due to small 
vessel disease (and very rarely to embolism), 
were found to be infrequently associated with AF 
in the Oxfordshire Community Stroke project 11. 
Finally, newer imaging techniques such as 
transoesophageal echocardiography and ultrafast 
CT. scan have made it easier to exclude 
intracardiac abnormalities which might be 
sources of embolism. 
Obviously some ischaemic strokes in AF are due 
to concomitant cerebrovascular disease, but the 
exact number is uncertain and controversial, and 
when all factors are considered NVAF is found 
to be an independent risk factor 12. 
Can Patients with AF be Stratified into 
Different Risk Groups for Embolism? 
A number of factors can be used to stratify risk 
levels, for example younger patients with 'Lone' 
AF have been shown to have an annual stroke 
risk of less than 0.5% 6,13 . 
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TABLE 11 - AF and Embolism 
Association Prevalence of 
embolism 
Mitral valve disease and AF 41 % 

Sinus rhythm with ischaemic 

heart disease 7 % 

Chronic AF with ischaemic 

heart disease 35 % 

Hinton et al (1977) 4 
At the onset of paroxysmal or sustained AF there 
is a particularly high risk of embolism. 14 
Embolic risk varies from 2.5% to 7.2% if either 
hypertension or congestive cardiac failure within 
the last three months or previous 
thromboembolism are present. Where two of 
these factors occur together, the risk rises to 
17.6% 15. Left atrial size and left ventricular 
dysfunction at echocardiography are also 
associated with a 5% thromboembolic risk, 
increased from 1 % with a normal 
echocardiogram 16. 
Can Stroke be Prevented in NVAF? 
This question has been addressed by five 
studies 17-21; comparing warfarin, aspirin and 
placebo. All have been terminated early, within 
two years, because the warfarin group had shown 
significant benefit and it was considered 
unethical to continue the trials. The average age 
of the patients was just under 70 years. Overall 
there was a reduction of ischaemic and embolic 
strokes in the warfarin group from 5% to 2%, 
which represents a 70% reduction in risk level. 
These figures applied ro a careful1y selected 
group with a high exclusion rate (up to 93%) and 
stringent haematological monitoring. For every 
1000 patients treated, there was an increase of 
three major haemorrhages. but in general the 
safety and efficiency of warfarin in the elderly 
was remarkable. 
On this data there was consensus that all patients 
with NV AF should be considered for 
anticoagulation, unless some contraindication 
existed. 
What Role for Aspirin? 
Until March 1994, the place of Aspirin was not 
established; it was compared in the AFASAK 
study 17 and the SPAF study 19 and was not as 
convincing as Warfarin. It seemed to reduce the 
risk of stroke by 25%, but the 95% confidence 
interval included zero benefit. 
The Stroke Prevention in Atrial Fibrillation II 
Study (SPAFII) 22 published in 1994 clarified 
the role of aspirin. 1,105 patients were 
randomised to warfarin (International 
Normalized Ratio (lNR) 2-4.5), or Aspirin 
325mgs daily to detect a reduction in primary 
ischaemic or systemic embolic events. There 
were two sub-groups divided by the age of 70 
years, and the trial was designed to detect a 2 % 
reduction in the events described above in the 
under 75 year olds, and a reduction of 4% in 
those over 75 years. Warfarin seemed to be 
more effective than Aspirin in the prevention of 
ischaemic strokes but the absolute reduction was 
small, and there was an increase in 
haemorrhagic strokes. Both drugs were equally 
effective in preventing total or disabling 
strokes. The absolute rate of events with aspirin 
in low risk under 75 year olds (ie no heart failure, 
thromboembolism or hypertension) was 0.5% 
annually. This implied that patient age and 
thromboembolic risk should be considered in 
tailoring antithrombotic treatment of NV AF. 
This study did not address the relative risks of the 
subgroups, however bearing in mind the factors 
affecting thromboembolic risk, patient selection 
should be based upon the clinical and 
echocardiographic findings. 
Who Should be Treated? 
This still requires the results of ongoing trials to 
define the subgroups of patients, the dosages 
and possible combinations of aspmn and 
warfarin. In the meantime it is clear that patients 
with a previous transient ischaemic attack or 
minor stroke should be anticoagulated 23. 
In the light of SPAF " 22, it seems that warfarin 
is also indicated in the presence of cardiac 
abnormalitIes as demonstrated by clinical or 
echocardiographic findings. Transoesophagea\ 
echocardiography may be helpful in stratifying 
the risk by better imaging of intracardiac 
thrombi and the left atrial appendage. 
The five studies originally addressing this 
problem 17-21 suggested that increasing age 
should not be a barrier to anticoagulation. On the 
contrary, the older the patient, the higher the risk 
of embolism and so the higher the benefit. 
However older patients also face an increased 
risk of bleeding, apart from problems due to 
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dementia / forgetfulness, difficulty in mobility 
and therefore access to an anticoagulant clinic. 
The studies had an exclusion rate of up to 93%, 
and in practice it is still unclear whether the 
stringent haematological control they achieved 
can be reproduced in routine clinics. In practice 
this means that one must balance the risks and 
benefits of each treatment and tailor therapy 
accordingly, so as to reduce the embolic risk of 
NVAF. 
What Level of Anticoagulation? 
Differing levels of anticoagulation were used in 
the trials with the INR varying from 1.4-4. The 
Veterans Affairs Study used prothrombin time, 
because INR was not as yet in general usage in 
North America. At present other trials are in 
progress and until they are completed an INR of 
2-3 as recommended by the American College 
of Chest Physicians 24 is thought to be 
reasonable, assuminb the haematological 
monitoring is of good quality. 
The average rate of intracerebral haemorrhage 
was 0.3% in the five trials 17-21; this was 
probably due to careful selection and follow up 
in the trials. However out-patient studies have 
shown serious haemorrhages in 5 to 11 % of 
patients and fatal bleeds in 2% in one year of 
routine medical care 25. Moreover, one study 
showed that the risk of intracerebral haemorrhage 
was increased ten-fold whilst on anticoagulant 
therapy, independently of age 26. Overall 
anticoagulant treatment is justified if the rate of 
serious cerebral bleeding is low: should it rise 
beyond 2% annually the complication rate would 
be too high to justify both medically and 
economically27. No figures are available for the 
Local Anticoagulant Clinic but in view of the 
increasing numbers of referrals for atrial 
fibrillation 28, they are necessary for guidance. 
What of the Secondary Prevention 
of Stroke? 
The European Atrial Fibrillation Trial (EAFT)24, 
supports anticoagulating patients who are in AF 
and have sustained a minor ischaemic stroke or 
Transient Ischaemic Attack (TIA). The risk of 
stroke was reduced from 12% to 4%. These 
patients were a selected subgroup with small 
strokes or TIA's, and the trial did not address the 
problem of those with larger strokes. 
Consideration should also be given to the 
wisdom and practicality of anticoagulating 
patients who are probably elderly, hypertensive 
and disabled, but in view of this data the 
possibility should at least be reviewed 29.30. 
Is the Long Term Benefit 
Really Established? 
All the studies were concluded within two years, 
so the question as to whether the risk of 
thromboembolism is constant in AF is unlikely to 
be formally evaluated. 
What are the Implications Regarding 
the Treatment of NVAF? 
In view of the inherent risks of AF, and the 
treatment necessary to reduce these risks, there 
ought to be a more aggressive approach in 
attempting to restore sinus rhythm. The action of 
digoxin is equivalent to placebo in restoring sinus 
rhythm, 31 so other therapeutic agents have to be 
considered. A rational approach could be a 
pharmacological trial of a class III 
Antiarrhythmic Agent (eg. amiodarone or 
sotalol) for one month. Should this be successful 
in restoring sinus rhythm a small maintenance 
dose as prophylaxis would seem reasonable 32, 
failing this, DC cardioversion could be 
attempted. A full discussion of the possible 
antiarrhythmic therapy is beyond the scope of 
this article but is available elsewhere 32 
Ant\coagulation should be continued for one 
month after restoration of sinus rhythm. 
A study in the British Heart Journal 33 showed a 
reluctance to consider cardioversion or 
anticoagulation for NV AF, however optimum 
management will require ll1creasing 
consideration of such factors. 
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J, 
digoxin for rate control 
uncompromised CVS fast-compromised CVS 
CLINICAL ALGORHYTHM: MANAGEMENT OF ATRIAL FIBRILLATION (AF) 
Identify any cause and treat. 
Aim to restore sinus rhythm wherever possible. 
A. ARRHYTHMIA 
Consider thyroid/unction tests, echocardiogram 
halter monitor (? sick sinlls syndrome) 
VALVULAR NON-V AL VULAR 
anticoagulate 

target INR 3.5 - 5 

~ 1
long standing recent or unknown 
t t 
Pharmacological DC cardioversion 

cardioversion with class 

III AAA (e.g. amiodarone x 1 month) 

'\, J 
Still in AF? Still in AF? 
1 t 
Consider DC Class III agent 
cardioversion x 1 month 
SR/ ~AF~ ~SR 
t t 

maintain with considtchang€ prophylaxis with 
class III AAA to digoxin for class III AAA 
rate control 
DC =Direct current AAA =Anti-arrhythmic agent CVS =Cardiovascular system 
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CLINICAL ALGORHYTHM: MANAGEMENT OF ATRIAL FIBRILLATION (AF) 
Identify any cause and treat. 
Aim to restore sinus rhythm wherever possible. 
B. ANTICOAGULATION 
Assess embolic risk and treat 
Low embolic risk 
- AF with 
No clinical radiological, or 
echocardiographic 
evidence of heart disease 
in those under 60 years 
(Lone AF) 
- No embolism 
- No thyrotoxicosis 
- No recent heart failure 
(within 3/12) 
- No hypertensi6n 
1 
Aspirin 325mg ~ 
High embolic risk 
- Fast AF 
- Thyrotoxic AF 
- Previous thromboembolism 
- Congestive cardiac failure 
within 3/12. 
- Hypertension (controlled) 
- Left atrial dilatation 
- Left ventricular dilatation 
1 
Consider 

anticoagulation 

target INR 2 - 3 

1d' .contram lcatlOns 
A and B are to be considered concurrently 
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